Steward Partners Investment Advisory’s Adaptimmune Therapeutics ADAP Stock Holding History

Steward Partners Investment Advisory’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,000	Closed	-$3K	–	2579
2019 Q3	$3K	Hold	2,000	–	–	﹤0.01%	2335
2019 Q2	$8K	Buy	+2,000	New	+$8.15K	﹤0.01%	2054
2018 Q4	–	Sell	-2,000	Closed	-$27K	–	791
2018 Q3	$27K	Hold	2,000	–	–	﹤0.01%	1420
2018 Q2	$24K	Hold	2,000	–	–	﹤0.01%	1384
2018 Q1	$22K	Hold	2,000	–	–	﹤0.01%	1290
2017 Q4	$13K	Buy	+2,000	New	+$15.4K	﹤0.01%	1262

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Steward Partners Investment Advisory's ADAP Position: Q4 2019 in Review

Steward Partners Investment Advisory sold out of Adaptimmune Therapeutics (ADAP) in Q4 2019, closing a stake of 2,000 shares — an estimated $3K sold.

Steward Partners Investment Advisory first reported a position in ADAP in Q4 2017 and held it in 6 quarters. The position peaked at $27K in Q3 2018. 43 funds tracked by Wall St. Rank hold ADAP as of Q4 2019.

Steward Partners Investment Advisory reported no remaining Adaptimmune Therapeutics position as of Q4 2019 after selling out during the quarter.
Steward Partners Investment Advisory sold 2,000 Adaptimmune Therapeutics shares in Q4 2019, an estimated $3K.
Steward Partners Investment Advisory first reported a position in Adaptimmune Therapeutics in Q4 2017 and held it in 6 quarters.
Steward Partners Investment Advisory's Adaptimmune Therapeutics position peaked at $27K in Q3 2018.
43 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2019.

Based on Steward Partners Investment Advisory's 13F filing for Q4 2019, filed 17 Jan 2020.